Buy A Cash-Rich Company's Stock? Maybe Not

ByRyan Perlowin:It is hard to tell who is soaring higher: shares of Netflix (NFLX) or the investors that saw a glimmer of hope just six months ago when the stock was trading at $55. With the stock currently trading at $170 (having come down after bouncing off of the $198 resistance level several times), those early-October visionaries have more than tripled their investment.

By TechCrunch: By Sarah Perez

By Bret Jensen:Apologies for a Christmas reference when we are still in October. However, it seemed appropriate to highlight a cheap cash rich tech stock named Rudolph Technologies (RTEC). Not only does it have a fortress balance sheet but it is posting double digit revenue increases and selling at a low valuation.

By Sammy Pollack:Recently, Steve Wozniak, Apple co-founder told CNBC that he believes Apple (AAPL) stock has the potential to hit $1,000 because the company has a "tremendous amount of growth ahead." I do not disagree that the company has tremendous growth ahead. However, I believe that government restrictions will prevent AAPL from hitting $1,000.

Rovi (ROVI), which provides on-screen TV guides and technology that protects against video piracy, has seen its stock climb some 10 percent since its December 23 announcement of a deal to purchase Sonic Solutions (SNIC), a key player in the emerging streaming video market.

The Japanese nuclear disaster reminds us of our frailty in the wake of man versus nature. Similar to Chernobyl, Japan's population will face higher cancer incidence rates, likely in the form of thyroid, sooner, and myeloma, later, as they’re the more commonly occurring cancers post exposure. As investors, we can be thankful biotechnology companies, including Celgene Corp. (CELG), are developing products to fight cancer. But is now the right time to buy?Celgene has some great attributes.

Frank Voisin submits: Lung Cancer is the number one cancer killer globally, claiming approximately 1.2 million lives annually. Non-Small Cell Lung Cancer (NSCLC) is the most common, accounting for 85% of lung cancers. Abraxis Bioscience was a biopharmaceutical company that was recently purchased by Celgene Corp. (CELG).

Trade Radar Operator submits: Outside of the stock market, last week was actually pretty decent. Here are some of the better things that happened: